INSP - Bragar Eagel & Squire P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Golden Heaven Inspire Medical and Driven and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG), Inspire Medical Systems, Inc. (NYSE:INSP), and Driven Brands Holdings, Inc. (NASDAQ:DRVN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG)
Class Period: April 13, 2023 - November 13, 2023
Lead Plaintiff Deadline: February 20, 2024
According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Golden Heaven's amusement parks are in generally poor condition; (2) Golden Heaven materially overstated the number of visitors to its amusement parks and overall growth prospects, and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
For more information on the Golden Heaven class action go to: https://bespc.com/cases/GDHG
Inspire Medical Systems, Inc. (NYSE:INSP)
Class Period: May 3, 2023 - November 7, 2023 (Common Stock Only)
Lead Plaintiff Deadline: February 20, 2024
Inspire Medical is a medical technology company that develops and commercializes minimally invasive products for patients with obstructive sleep apnea ("OSA") that require prior authorizations from doctors. In 2022, Inspire Medical introduced a pilot program (the "Acceleration Program") through which the Company's Advisor Care Program team, with the customer on the phone, would directly access doctors' electronic schedules and schedule doctor appointments online, without the need for phone calls. Throughout the Class Period, Defendants touted the Acceleration Program's effectiveness, claiming that the program had achieved a "30% improvement in physician appointments," and that by August 2023, "about 60-plus centers are using the tool right now."
The Class Action alleges that, during the Class Period, Defendants misled investors and/or failed to disclose that: (1) despite the Acceleration Program, customers were encountering challenges with the prior authorization submission process, including with the scheduling of appointments; (2) a slowdown in prior authorization submissions arising from these challenges led to a shortfall of hundreds of procedures to implant the Company's ...